Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Putting some spine into alternative splicing.

Bernard Khoo1, Scott A Akker, Shern L Chew

  • 1Department of Endocrinology, St Bartholomew's Hospital, London EC1A 7BE, UK.

Trends in Biotechnology
|August 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prednisolone Once Daily vs Hydrocortisone Thrice Daily in Hypoadrenalism: A Randomized Clinical Trial.

JAMA network open·2026
Same author

<sup>177</sup>Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence.

Endocrine oncology (Bristol, England)·2025
Same author

<sup>68</sup>Ga-DOTA-TATE PET/CT improves accuracy and guides management in multiple endocrine neoplasia type 1 (MEN-1) patients with suspected duodeno-pancreatic neuroendocrine tumours.

Endocrine oncology (Bristol, England)·2025
Same author

GLP-1 and amylin receptor multiagonism with amycretin for obesity management.

Lancet (London, England)·2025
Same author

Reassessing the role of the p.(Arg304Gln) missense AIP variant in pituitary tumorigenesis.

European journal of endocrinology·2025
Same author

Neuroendocrine tumours and pregnancy: Real-world data from an European Neuroendocrine Tumour Centre of Excellence.

Journal of neuroendocrinology·2024
Same journal

Bacterial spores as a modular platform for the production of amyloids for materials.

Trends in biotechnology·2026
Same journal

The oriGen case and Mexico's regulatory blind spots in genomic biobanking.

Trends in biotechnology·2026
Same journal

A caspase-3-activated protein expression system for apoptosis visualization and apoptosis-pyroptosis conversion to boost antitumor activity.

Trends in biotechnology·2026
Same journal

Over 4 months of ethylene production using solid-state photosynthetic cell factories.

Trends in biotechnology·2026
Same journal

Closing the nitrogen loop in groundwater with biohybrid technologies.

Trends in biotechnology·2026
Same journal

Engineering environmental bacteria for whole-cell PET hydrolysis and assimilation.

Trends in biotechnology·2026
See all related articles

Spinal muscular atrophy (SMA) is a neurodegenerative disease. Small synthetic molecules can correct the splicing defect in the SMN2 gene, offering potential for new SMA treatments.

Area of Science:

  • Genetics
  • Molecular Biology
  • Neuroscience

Background:

  • Spinal muscular atrophy (SMA) is a neurodegenerative disorder stemming from mutations in the SMN1 gene.
  • The SMN2 gene, while homologous, cannot fully compensate for SMN1 defects due to a specific mutation affecting exon 7 splicing.
  • This leads to exon 7 exclusion, a key factor in SMA pathogenesis.

Discussion:

  • Two recent studies highlight the efficacy of small synthetic effectors in correcting the SMN2 exon 7 splicing defect.
  • These molecules specifically target the aberrant splicing mechanism characteristic of SMA.
  • The findings suggest a novel therapeutic strategy for SMA and related splicing disorders.

Key Insights:

  • Targeted correction of SMN2 exon 7 splicing is achievable with small synthetic molecules.

Related Experiment Videos

  • This approach directly addresses a fundamental molecular defect in spinal muscular atrophy.
  • The specificity of these effectors is crucial for their therapeutic potential.

    • Outlook:

    • These findings open new avenues for developing targeted therapies for spinal muscular atrophy.
    • The synthetic effector approach may be applicable to other genetic diseases caused by splicing defects.
    • Further research is warranted to translate these findings into clinical applications for patients with SMA.